PPM1K and maple syrup urine disease: Currently there are no FDA-approved drug therapies for the long-term management of MSUD, although a small number of patients with a specific mutation in the thiamine binding site in the E1b subunit of BCKDH (30–40% activity), are known to respond to thiamine supplementation11.